文献速递衰弱、肌少症与跌倒老年综合评估老年慢病共病管理

老年癌症患者Geriatric 8衰弱与健康相关生活质量的关系:PROGNOSIS-G8研究

Association between Geriatric 8 frailty and health-related quality of life in older patients with cancer (PROGNOSIS-G8): a Danish single-centre, prospective cohort study.
PubMed 文献 · Lancet Healthy Longev · 2024-08-29

这项丹麦单中心前瞻性队列研究纳入70岁及以上因实体瘤转诊肿瘤评估的患者,用Geriatric 8筛查衰弱(评分≤14),并在基线及3、6、9、12个月完成EORTC QLQ-C30和ELD14问卷。调整性别、治疗意图和癌症类型后,衰弱患者各时间点的总体健康状况和总结评分均显著低于非衰弱患者。

要点

  • 衰弱(G8≤14)老年癌症患者总体健康状况在基线及12个月内各随访点均显著更差。
  • 衰弱患者EORTC总结评分在基线及3、6、9、12个月均显著低于非衰弱患者。
  • 衰弱患者身体功能、角色功能、活动能力和疲乏结局显著更差,家庭支持无差异。

核心结论

  • 老年癌症患者中,衰弱者在肿瘤转诊后12个月内健康相关生活质量显著差于非衰弱者。
  • 识别并治疗衰弱可能最终改善患者健康相关生活质量。

研究设计与样本

  • 丹麦单中心前瞻性队列研究,2020年6月1日至2021年10月15日筛查1398例70岁及以上因实体瘤转诊肿瘤评估的患者。
  • 908例(65%)存在衰弱(G8≤14),490例(35%)无衰弱;707例(51%)提供生活质量数据(衰弱437例,非衰弱270例)。
  • 使用EORTC QLQ-C30和ELD14问卷在基线及3、6、9、12个月评估,采用线性混合模型分析并调整性别、治疗意图和癌症类型。

关键数值与推荐

  • 衰弱定义为Geriatric 8评分≤14。
  • 主要结局为EORTC QLQ-C30中两个七点Likert问题测量的总体健康状况和QoL。
  • 次要结局包括EORTC总结评分、五个功能量表(身体、角色、社会功能、维持目的、家庭支持)和五个症状量表(疲乏、疼痛、活动能力、未来担忧、疾病负担)。

临床怎么用

  • 对70岁及以上转诊肿瘤评估的实体瘤患者,可用Geriatric 8筛查衰弱。
  • 对G8≤14的衰弱患者,应关注其健康相关生活质量在12个月内可能持续较差。
  • 识别衰弱并给予治疗,可能有助于改善老年癌症患者的生活质量。

局限性

  • 本研究为丹麦单中心前瞻性队列研究。
  • 仅51%的筛查患者提供了健康相关生活质量数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Health-related quality of life (HRQoL) is highly valued among older adults with cancer. The Geriatric 8 screening tool identifies individuals with frailty, but its association with HRQoL remains sparsely investigated. Herein, we evaluate whether Geriatric 8 frailty is associated with short-term and long-term HRQoL in older patients with cancer. METHODS: In this Danish single-centre, prospective cohort study, patients aged 70 years and older, referred to oncological assessment for solid cancers, were screened with the Geriatric 8. Patients completed the European Organisation for Research and Treatment of Cancer (EORTC) Quality-of-Life Core 30 (QLQ-C30) and Elderly 14 (ELD14) questionnaires at baseline, 3 months, 6 months, 9 months, and 12 months. Patient characteristics were obtained from medical records. Differences in mean global health status and QoL (GHS), measured using the two seven-point Likert scale questions from the EORTC QLQ-C30 regarding overall health and QoL during the past week, between patients with frailty (defined as a Geriatric 8 score of ≤14) and without frailty within 12 months were the primary outcome. Secondary outcomes were differences in the mean EORTC Summary Score comprised of all questions from the QLQ-C30 except for those included in the GHS and a question concerning financial difficulties, and five functional (physical, role, and social functioning, maintaining purpose, and family support from the EORTC QLQ-C30 and the EORTC-QLQ-ELD14), and five symptom scales (fatigue, pain, mobility, future worries, and burden of illness from the EORTC-QLQ-C30 and the EORTC-QLQ-ELD14). Analyses were done using linear mixed models. All primary and secondary outcomes were adjusted for gender, treatment intent, and cancer type and the primary outcome was also assessed by means of a responder analysis. FINDINGS: Between June 1, 2020 and Oct 15, 2021, 1398 eligible patients were screened with the Geriatric 8 (908 [65%] with frailty and 490 [35%] without frailty) and provided medical record data. Of these patients, 707 (51%) also provided HRQoL data (437 [62%] with frailty and 270 [38%] without frailty). When adjusted, patients with frailty had poorer GHS (-15·1, 95% CI -18·5 to -11·6; p<0·0001) at baseline and throughout follow-up (3 months -7·4, -11·0 to -3·7, p=0·0001; 6 months -11·7, -15·5 to -7·9, p<0·0001; 9 months -10·4, -14·3 to -6·5, p<0·0001; 12 months -10·4, -14·6 to -6·2, p<0·0001) compared to patients without frailty. Adjusted summary scores were also poorer for patients with frailty (-9·9, 95% CI -12·1 to -7·6; p<0·0001) compared to patients without frailty at baseline and throughout follow-up (3 months -8·2, -10·5 to -5·8, p=0·0001; 6 months -9·0, -11·4 to -6·6, p<0·0001; 9 months -9·2, -11·7 to -6·8, p<0·0001; 12 months -8·9, -11·5 to -6·3, p<0·0001). Patients with frailty had significantly worse physical and role functioning, mobility, and fatigue outcomes, with no differences in family support within 12 months, at all timepoints. INTERPRETATION: Older patients with cancer and frailty have significantly poorer HRQoL than those without frailty within the 12 months following an oncology referral. Thus, by identifying and treating frailty, we can ultimately improve patient HRQoL. FUNDING: The Danish Cancer Society, Academy of Geriatric Cancer Research (AgeCare), Odense University Hospital, University of Southern Denmark, Dagmar Marshalls Fond, and Agnes and Poul Friis Fond.

来源:Lancet Healthy Longev,查看原文。版权归原作者所有。

引用

  1. Ditzel HM, Giger AW, Lund CM, et al. Association between Geriatric 8 frailty and health-related quality of life in older patients with cancer (PROGNOSIS-G8): a Danish single-centre, prospective cohort study. Lancet Healthy Longev. 2024. PMID: 39217995. doi:10.1016/S2666-7568(24)00118-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。